Idelalisib
Pre-clinicalTerminated 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Absence of Signs or Symptoms
Conditions
Absence of Signs or Symptoms, B-Cell Non-Hodgkin Lymphoma, Digestive System Signs and Symptoms, Indolent Adult Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma
Trial Timeline
Feb 1, 2016 → Jun 5, 2018
NCT ID
NCT02928510About Idelalisib
Idelalisib is a pre-clinical stage product being developed by Gilead Sciences for Absence of Signs or Symptoms. The current trial status is terminated. This product is registered under clinical trial identifier NCT02928510. Target conditions include Absence of Signs or Symptoms, B-Cell Non-Hodgkin Lymphoma, Digestive System Signs and Symptoms.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03568929 | Pre-clinical | Completed |
| NCT02739360 | Approved | Terminated |
| NCT02928510 | Pre-clinical | Terminated |
| NCT02536300 | Phase 3 | Terminated |
| NCT02590588 | Phase 2 | Terminated |
| NCT02242045 | Phase 1 | Completed |
| NCT01539291 | Phase 3 | Terminated |
| NCT01393106 | Phase 2 | Completed |
| NCT01282424 | Phase 2 | Completed |
| NCT01306643 | Phase 1/2 | Completed |
| NCT01090414 | Phase 1/2 | Terminated |
Competing Products
9 competing products in Absence of Signs or Symptoms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| topiramate | Johnson & Johnson | Phase 2 | 52 |
| rapamune, mycophenolate mofetil and steroid + tacrolimus, sirolimus and steroid | Pfizer | Pre-clinical | 22 |
| Brivaracetam Film-coated tablet + Brivaracetam oral solution | UCB | Phase 3 | 74 |
| Brivaracetam Film-coated tablet + Brivaracetam oral solution | UCB | Phase 3 | 74 |
| Levetiracetam | UCB | Phase 2 | 49 |
| Brivaracetam | UCB | Phase 3 | 74 |
| Sativex and rifampicin + Sativex and rifampicin + Sativex and ketoconazole + Sativex and ketoconazole + Sativex and omeprazole + Sativex and omeprazole | Jazz Pharmaceuticals | Phase 1 | 30 |
| Cannabidiol (Epidiolex) | Jazz Pharmaceuticals | Approved | 82 |
| BMB-101 | Bright Minds Biosciences | Phase 2 | 47 |